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Abstract  
 
Movement disorders in childhood comprise a wide spectrum of both genetic and 
acquired diseases, ranging from benign self-limiting conditions to more 
progressive phenotypes associated with significant morbidity and mortality. 
Elucidation of the underlying cause is achieved through accurate history, detailed 
clinical examination and, where appropriate, neuroimaging and laboratory 
investigations. In this review, the key clinical features of diseases that present in 
childhood will be discussed, including benign, genetic, acquired and psychogenic 
movement disorders. Early accurate diagnosis will facilitate the instigation of 
appropriate management strategies. 
 
Purpose of Review  
 
The aim of this review is to provide an overview of movement disorders that 
present in childhood. Key clinical features will be discussed, as well as a brief guide 
to management strategies. There is also a focus on recent advances in the field of 
pediatric movement disorders. 
 
Learning Objective 
 
To understand the broad spectrum of movement disorders that may present in 
childhood and have awareness of latest advances in the field. 
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Introduction 
Movement disorders in childhood comprise a heterogeneous group of conditions 
that lead to impairment of voluntary movement, abnormal postures or inserted 
involuntary movements.  Movement disorders in children are often classified into 
two main categories, namely hyperkinetic/dyskinetic movement disorders 
(including stereotypies, tics, tremor, dystonia and chorea)1 and hypokinetic 
movement disorders, encompassing parkinsonian phenotypes2. A number of 
other classification systems are also recognized, subgrouping disorders according 
to temporal and spatial patterns, clinical features, motor semiology and 
underlying aetiology (molecular genetic features and/or neuropathology).  
 
A wide range of movement disorders are described in childhood, from benign, self-
limiting transient phenomena to more progressive disorders associated with 
significant morbidity and mortality. Movement disorders in childhood may 
present acutely, sub-acutely or in a more chronic manner. The underlying 
aetiologies for childhood movement disorders are diverse, and include both 
acquired and genetic conditions. In recent times, significant advances in genetic 
technologies have facilitated the discovery of a number of novel disease-causing 
genes and movement disorder syndromes in childhood.  
 
Accurate diagnosis of childhood onset movement disorders requires careful 
ascertainment of clinical history, detailed neurological examination (for 
recognition of phenomenology and associated features) and a broad knowledge of 
potential differential diagnoses. In this review, an updated overview of movement 
disorders in childhood will be provided, with particular focus on newly recognized 
conditions. 
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(1) Benign Movement Disorders of Childhood 
A number of relatively benign movement disorders of childhood are described, 
relating to specific stages of normal development (Table 1)3. The underlying basis 
of such movement disorders is not fully understood, but some are thought to be a 
manifestation of the developing brain, reflecting central nervous system 
immaturity.  The majority of these conditions occur early in life, during the 
neonatal period, infancy and early childhood, with resolution of symptoms over 
time. Furthermore, other neurological symptoms are rarely present, and most 
children are found to have a normal neurological examination. Accurate 
recognition is crucial to avoid unnecessary neurological investigations and 
provide families with reassurance regarding long-term prognosis, where 
appropriate.  
[AU: Thank you for providing Key Points for your article; however, we like 
to have about one key point per manuscript page, so please provide an 
addition 10 to 15 key points for your article and put them after the 
paragraph in which they should appear.] 
Key Point 1:  
A number of benign movement disorders of childhood are recognized, which 
are transient in nature, and usually have a good long-term prognosis 
 
(2) Tics, Tourette Syndrome and Stereotypies 
Tics are the most common movement disorder in childhood, and can be separated 
into motor tics or vocal tics. Motor tics typically involve the face, head and 
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shoulders, although can affect any body part. The characteristic features of tics are 
their repetitive, stereotypical nature, the fluctuating nature (wax and wane), 
suppressibility, and suggestibility. Despite being common (transient tics affect 
~5-10% of children at some time, and Tourette syndrome affects 0.5% of 
children), these disorders remain poorly understood and recognized by clinicians 
and lay people. Patients are often referred to opticians (blinking, eye movements), 
ENT clinicians (throat clearing) and respiratory physicians (repetitive cough) 
before a diagnosis is made. Tics are often mis-labelled as ‘habits’. The first priority 
is a confident diagnosis, and education of the child, family and school that 
tics/Tourette is a neurobiological ‘brain’ condition, and tolerance and acceptance 
is required. The fact that tics peak between 10-12 years and typically reduce in 
severity thereafter is comfort to families, and an important component of 
counseling. The second priority is to define how impairing the tics are on the 
child’s function and psychological well-being. When the tics are affecting the 
child’s function significantly, therapeutic intervention can be considered including 
tic reversal therapy delivered by psychologists, or medical therapies such as 
alpha-agonists (guanfacine, clonidine) and when severe and impairing function, 
neuroleptics such as risperidone. The third priority is to determine whether co-
morbidities such as attention deficit disorder, anxiety, obsessive-compulsive 
disorder are present, as these can be more impairing than the tics, and are 
arguably more treatable than tics with psychological or medical interventions. 
Neurodevelopmental disorders are also over-represented in patients with 
Tourette syndrome, and a significant minority of patients may have autistic 
spectrum disorder, sensory processing disorder, or other dysexecutive problems, 
which can affect school and general functioning. Tourette syndrome is not a 
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disease, but instead a ‘symptom syndrome’ and the aetiology is likely multi-
factorial with genetic vulnerability factors plus environmental factors4 (Ganos and 
Martino, 2015).  
Stereotypy is a common movement phenotype, and is a normal feature of infant 
development, but when stereotypy continues beyond this period the episodes can 
become concerning to parents (less for the child) because of the unusual nature of 
the episodes and the potential for social stigmatization. Stereotypies are repetitive 
movements and classic examples include rocking, flapping and ‘body-tensing’, 
however some stereotypies are extremely complex including twisting, grimacing 
and posturing. The most important characteristics are the stereotypical nature of 
the movements (the episodes are similar), are partially distractible (although the 
child may subsequently need to complete the movement after being distracted), 
and the fact that episodes are often more likely to occur with certain stimuli such 
as excitement or anticipation (waiting in a queue), a favourite activity (watching 
TV), or sometimes boredom (sitting in back of car). Parental videos are essential 
for diagnosis, and are highly informative. Stereotypy is more common in children 
with developmental disorders such as language delay and autistic spectrum 
disorder, but complex motor stereotypy can also occur in normally developed 
children5. Detailed assessment for subtle neurodevelopmental disorders is 
important as this may present therapeutic options, although the treatment of 
stereotypy itself is challenging and drugs are ineffective, although psychological 
approaches may be useful in well motivated, cognitively able individuals. Many 
normally developed older children with stereotypy have associated 
neuropsychiatric conditions such as ADHD, anxiety or tics5. Some children with 
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complex stereotypy describe complex, sometimes imaginary thoughts during the 
movements6. 
 
Key Point 2: 
Tics and stereotypy are the most common movement disorders of 
childhood. Diagnosis is dependent on careful history, observation and 
parental videos. Education of the family, and searching for 
neurodevelopmental and neuropsychiatric comorbidty is paramount, as 
associated comorbidities such as anxiety and OCD can exacerbate the 
movements, and are arguably more amenable to psychological or medical 
treatments.  
  
(3) Acquired Movement Disorders  
(i) Cerebral palsy (hypoxic ischaemic) 
The classic movement disorder cerebral palsy phenotype is ‘dystonic CP’ although 
other terms such as ‘dyskinetic CP’ or ‘choreoathetoid CP’ are sometimes used 
dependent on the movement phenomenology. Classic teaching is that dystonic CP 
occurs as a consequence of hypoxic ischaemic injury predominantly to the 
subcortical structures during early brain development. Although a clear history of 
brain injury is present in a proportion of cases, there is no history in a significant 
proportion, and many patients with dystonia CP have a normal MRI. It is 
increasingly likely that some patients labeled as ‘dystonic CP’ in fact have a genetic 
movement disorder, or instead have other disease mechanisms. A positive family 
history of neurological disease, a fluctuating course, apparent initial normal early 
development, a normal MRI and clinical features such as progressive dystonia, 
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exercise induced dystonia, or oculogyric crises are some features that should alert 
the clinician to the possibility this is not ‘typical’ dystonic CP.  
 
(ii) Infectious 
Direct CNS infection resulting in encephalitis does not commonly result in 
movement disorders, but would be more typically observed in autoimmune 
encephalitis (discussed below). However there are a number of infections that can 
affect subcortical structures resulting in movement disorders. The most 
important worldwide cause is Japanese encephalitis, which remains endemic in 
certain parts of the world, especially Asia, and commonly results in a severe 
dystonic-akinetic phenotype7. Other infections that can affect subcortical 
structures and result in movement disorders include Epstein-Barr virus, 
enterovirus, Group A Streptococcus, Influenza and mycoplasma pneumoniae, 
amongst others. Whether these encephlitides are due to direct invasion of the CNS 
by the microorganism, or are post-infectious or immune-mediated is not always 
clear, and both mechanisms appear to be possible and may overlap. One of the 
most important examples of this overlap between infection and autoimmunity is 
the post-herpes simplex encephalitis relapse syndrome. In the weeks after 
presentation with typical herpes simplex encephalitis, 20% of patients will 
relapse with encephalopathy and movement disorders (typically chorea). During 
the relapse, the CSF no longer demonstrates positive herpes simplex PCR, but 
instead the CSF harbors autoantibodies against the NMDA- receptor8,9. These 
patients benefit from immune suppression. This syndrome therefore represents a 
prototypic example of infection-triggered autoimmunity10.  
 
(iii) Post-infectious/ Autoimmune 
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The presence of movement disorders in the context of encephalitis is strongly 
predictive of an autoimmune encephalitis, particularly anti-NMDAR 
encephalitis11. Almost all children with anti-NMDAR encephalitis have movement 
disorders, and young children often have generalized chorea and dystonia which 
is often impairing, whereas older children and adults are more likely to have more 
localized movements of the face, such as oro-buccal dyskinesia. In children, almost 
any movement disorder is possible in the course of disease, and the movements 
typically evolve over the course of disease with chorea, dystonia, stereotypy, 
akinesia and tremor all observed. Arguably the most characteristic movement 
disorders of anti-NMDAR encephalitis are the repetitive, stereotypical clonic or 
tonic posturing that result in purposeless, repetitive and sometimes violent 
agitated movements12. Some of the postures can be reminiscent of the syndrome 
catatonia. The movements rarely occur in isolation, but instead are part of a 
complex evolving encephalopathy syndrome with aphasia, psychosis, agitation, 
dysautonomia, as well as non-specific encephalitis features such as seizures and 
confusion. The syndrome is now very recognizable, and if suspected, immune 
suppressive therapy should be started whilst awaiting CSF and serum NMDAR 
antibodies. Early treatment and the willingness to use second line immune 
therapy (rituximab and/or cyclophosphamide) improve outcomes and reduce 
relapses13.  
 
Other autoimmune encephalopathies include ‘basal ganglia encephalitis’ which is 
a rare pure basal ganglia inflammatory encephalitis with restricted inflammation 
of the basal ganglia, typically presenting in young children with dystonia and 
akinesia, or sometimes chorea, plus change in behaviour14. Early use of steroids, 
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immunoglobulin and plasma exchange can improve outcomes and reduce the 
chance of residual atrophy and gliosis of the basal ganglia. These patients may 
harbor autoantibodies against dopamine-2 receptor.  
 
Sydenham chorea is still endemic in the world, and remains one of the more 
common causes of acute chorea. Triggered by beta-haemolytic strepotoccus as 
part of rheumatic fever, Sydenham chorea is a neuropsychiatric syndrome with 
acute behavioural change in addition to chorea. Although the disease is usually 
monophasic and self-resolving, a significant proportion of patients are left with 
minor chorea or residual neuropsychiatric disease, and for this reason it can be 
argued that patients should be treated with acute immune therapy, as there is 
some evidence that this can improve short term outcomes15, although long term 
data is lacking.  
 
Infection mediated tics and emotional lability, either as a post-streptococcal 
phenomenon (PANDAS) or post-infectious phenomenon (Pediatric acute 
neuropsychiatric syndrome, PANS) is an uncommon entity, and although tics are 
part of the syndrome, the acute anxiety, separation anxiety and obsessive-
compulsive symptoms with repetitive urination are more characteristic features 
of PANS16. Although these entities are clearly infection-associated and may benefit 
from antibiotics or immune modulation, the evidence that these disorders are 
definitely autoimmune is lacking at this time.  
 
Progressive encephalopathy with rigidity and myoclonus (PERM) is a rare 
syndrome considered part of the ‘stiff-person syndrome’ spectrum and is 
associated with glycine receptor antibodies17. More common in adults, this 
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syndrome has been described in young children who present with mild 
encephalopathy, irritability, rigidity and stimulus induced startle, which is 
distressing. The syndrome is an autoimmune version of genetic hyperekplexia and 
given the immune therapy responsiveness of PERM, it is important to recognize. 
Autoantibodies against DPPX (a subunit of potassium channel) can be associated 
with an autoimmune encephalitis associated with diarrhoea, weight loss, 
encephalopathy and movement disorders such as myoclonus, rigidity and 
startle18. And finally, autoantibodies against GABA-A receptor can sometimes be 
associated with autoimmune encephalitis and movement disorders, although 
status epilepticus appears to be the dominant phenotypic association of this 
autoantibody19.  
 
Opsoclonus myoclonus ataxia syndrome is a recognizable entity that can be 
infection-triggered, paraneoplastic (neural crest tumours) or ‘idiopathic’. The 
diagnosis is clinical and there is no defining autoantibody. Suspicion should result 
in screening for neural crest tumours, and giving immune therapy. Some patients 
appear to respond quickly to steroids and IVIG, whereas others require rituximab 
or more chronic immune suppression. General principles of treatment include 
early intervention, induction of complete remission avoid residual symptoms as 
this may infer ongoing inflammation and risk of permanent neurocognitive 
disability20. More aggressive intervention appears to have changed the natural 
history of this condition, with better outcomes now described21.   
 
In conclusion, although rare, the emergence of such autoimmune 
encephalopathies have radically changed the clinical approach to the child with 
acute autoimmune movement disorders. Rather than observation and 
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symptomatic therapy, there is increasing willingness to use immune therapies as 
early recognition and intervention appears to improve outcomes.  
Insert Clinical Vignette Case 1 
 
(iv) Stroke and other space-occupying lesions 
Any patient presenting with an acute movement disorder requires neuroimaging, 
and MRI is the optimal modality. Hemi-movement disorders can be caused by 
acute vascular events such as stroke or vasculitis, and MRI with diffusion weighted 
imaging is part of the diagnostic pathway. Moyamoya and other vasculopathies 
may present with chorea and surgical interventions can improve the movement 
disorders and reduce risk of ongoing stroke22. Likewise, tumours or other space 
occupying lesions involving the subcortical structures may present with acute or 
subacute onset of movement disorders, and imaging is diagnostic.  
 
(v) Toxic/iatrogenic 
Iatrogenic or toxic mechanisms are important causes of movement disorders, but 
are usually moderately straightforward to diagnose as there is usually a clear 
temporal association of drug usage and onset of movement disorder. Direct 
questioning regarding potential drug ingestion would therefore be an important 
part of the clinical history in children who acutely present with involuntary 
movements or postures. More common associations include neuroleptic induced 
dystonia/neuroleptic malignant syndrome, anti-epileptic induced dyskinesias in 
(often genetic) epilepsies, amphetamine or other stimulant use or misuse, 
withdrawal movement disorders such as with midazolam infusion withdrawal, 
and cancer-drug use resulting in movement disorders often with 
leukoencephalopathies23.  
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 (vi) Treatment strategies for acquired movement disorders  
The primary approach to the child with acquired movement disorders is defining 
the aetiology and then treating the underlying cause. Defining and treating the 
cause of disease in a timely fashion provides the best chance of a good outcome 
and reduces the potential destructive nature of disease. Symptomatic treatment 
of acquired movement disorders is generally unsatisfactory, and patients with 
autoimmune movement disorders appear to be vulnerable to drug adverse events, 
for example neuroleptics can induce akinesia and neuroleptic malignant 
syndrome in Sydenham chorea and anti-NMDAR encephalitis, respectively24. 
Agents such as benzodiazepines, alpha-agonists may be safer treatments of 
acquired movement disorders, but the evidence base is limited.  
 
Key Point 3: 
Acquired movement disorders have multiple potential causes. Although 
investigations such as MRI, CSF and autoantibody testing are important, it 
cannot be over-estimated that a careful clinical history and examination for 
specific movement disorder phenomenology is essential. Focus should be on 
defining the aetiology and providing specific targeted intervention. The 
concept of early recognition and intervention is increasingly emphasised.  
 
(4) Genetic Movement Disorders 
Advances in molecular genetic techniques such as chromosomal microarray 
studies, targeted next generation multiple gene panels and whole exome/genome 
sequencing strategies have led to significant increase in the diagnosis of genetic 
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movement disorders of childhood. Furthermore, a large number of new genetic 
disorders have been identified and clinically characterized.  
 
(i) Primary Genetic Dystonia  
Traditionally genetic dystonias have been classified according to a DYT number 
assigned to each disease locus. Paroxysmal disorders have also been assigned DYT 
numbers, and are discussed below [Section 4(iii)]. The most common forms 
presenting early in life, are DYT1, DYT5 and DYT11 dystonia, but DYT12, DYT23 
and DYT26 may also present in childhood (Table 2). DYT1-early onset primary 
generalized torsion dystonia is inherited in an autosomal dominant manner with 
incomplete penetrance (30-40%)25. It is due to mutations in TOR1A encoding 
torsinA, postulated to have a role in the regulation of subcellular compartments 
such as the nuclear envelope and endoplasmic reticulum. The vast majority of 
patients harbor the common GAG deletion. Symptom onset is usually in childhood 
or early adolescence, with dystonia usually beginning in one limb. In many 
patients, generalised dystonia usually ensues within 5 years of presentation.  
 
DYT5 represents disorders of neurotransmission secondary to inherited dopa-
responsive defects in the dopamine synthesis pathway. GTP cyclohydrolase 
deficiency, also known as Segawa’s disease, is due to heterozygous mutations in 
GCH1, with incomplete penetrance26.  Affected patients present from early 
childhood with limb dystonia, which can often mimic the symptoms and signs of 
diplegic cerebral palsy. Atypical disease presentations, including writer’s cramp, 
dystonic tremor and exercise-induced dystonia have all been described27. More 
recently there have been reported associations of GCH1 carriers manifesting early 
onset Parkinson’s disease28. DYT5b, tyrosine hydroxylase deficiency represents 
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another form of dopa-responsive dystonia, but is more complex, often with 
concurrent features of parkinsonism, other motor semiology and 
neurodevelopmental delay29 [Section 4(iv) Though response to L-dopa can lead 
to significant clinical benefit in Type B (hypokinetic rigid phenotype), the earlier 
onset Type A subtype, associated with neonatal encephalopathy, is more drug 
resistant. TH deficiency is likely a phenotypic spectrum with a number of 
intermediate forms. Patients with TH deficiency often require much higher doses 
of L-dopa than in autosomal dominant GCH1 deficiency for a therapeutic response.   
 
DYT11, or myoclonus dystonia syndrome has clinical onset in childhood (median 
age 5 years), and frequently presents with early myoclonus affecting the upper 
limbs and neck with predominantly upper (but also lower) limb dystonia30. More 
pronounced truncal involvement is evident later in childhood and adolescence. 
Alcohol responsiveness is sometimes reported in older patients. Comorbid 
neuropsychiatric features are commonly reported. Affected patients have 
hetererozygous mutations in SGCE, encoding the ε-sarcoglycan protein. Disease 
mechanisms are not yet fully elucidated but mutations are postulated to impair 
targeting of ε-sarcoglycan to the plasma membrane, affecting proteosomal 
degradation, protein glycosylation and ectodomain shedding.  
 
DYT12 is a rarer cause of genetic dystonia-parkinsonism due to autosomal 
dominant mutations in ATP1A3, encoding the α3 subunit of the Na+/K+-ATPase 
pump. Affected patients usually present acutely or sub-acutely (from over a few 
minutes–months) with rostrocaudal progression of dystonia-parkinsonism and 
significant bulbar dysfunction. More recently it has become clear that the clinical 
spectrum of ATP1A3-related disease is broad, encompassing a number of other 
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overlapping phenotypes including alternating hemiplegia of childhood as well as 
Cerebellar ataxia, Areflexia, Pes cavus, Optic atrophy, and Sensorineural hearing 
loss (CAPOS) syndrome31. The reasons for this phenotypic pleiotropy may be 
mutation dependent, but are yet to be fully elucidated. 
 
Heterozygous mutations of CACNA1B and KCTD17 have recently been described 
in extended kindreds with childhood-onset myoclonus dystonia32,33. Cardiac 
arrhythmias are additionally reported in those with CACNA1B variant p.R1389H. 
CaV2.2 channels carried less current when compared with WT channels and it is 
postulated that such altered channel properties could affect neurotransmitter 
release at excitatory and inhibitory channels. Screening of another myoclonus 
dystonia patient cohort for this missense change has not identified further cases, 
with observation of this rare variant in control populations. The significance of 
this mutation remains yet to be fully determined34. KCTD17 is postulated to show 
significant putaminal expression, and mutations thought to impair endoplasmic 
reticulum-dependent calcium signaling.  
 
(ii) Genetic Chorea 
A number of genes causing primarily choreiform dyskinesia are now reported. 
Often children with such conditions manifest chorea as part of a complex 
neurological disorder, as exemplified by FOXG1 syndrome.35 
 
Benign hereditary chorea (BHC) is a childhood onset hyperkinetic movement 
disorder due to mutations in NKX2.136. Hypotonia is commonly described in 
infancy, with onset of chorea from 2.5-3 years of age.  Chorea is usually generalized 
and may be exacerbated by excitement or stress. Patients often frequently 
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manifest neonatal/infantile respiratory symptoms (including respiratory distress 
syndrome, obstructive airways disease and chronic interstitial lung disease) and 
thyroid abnormalities (congenital hypothyroidism). NKX2.1, from the natural 
killer (NK) gene family of highly conserved homeodomain-containing 
transcription factors is postulated to have a role in embryonic development of the 
brain, lung and thyroid gland. The combination of chorea with thyroid 
abnormalities are also described in Allan Herndon Dudley Syndrome (AHDS), an 
X-linked disorder associated with mutations in SLC16A2 encoding the 
monocarboxylate transporter 8 (MCT8)37. Mutations lead to loss-of-function of 
this thyroid transporter, thereby impairing triiodothyronine transport capacity. 
Triiodothyronine has an important role in oligodendrocytes, inducing 
differentiation of the precursor, as well as acting as a survival factor in these cells, 
and influencing the distribution of myelin-related proteins. Affected individuals 
with AHDS present with profound hypotonia and early limb spasticity. A complex 
movement disorder evolves over time, with prominent chorea, but also dystonia.  
 
In 2014, mutations in MICU1 were identified in patients with cognitive 
impairment, proximal myopathy and a progressive choreiform movement 
disorder38. MICU1 is a regulator of MCU, a Ca(2+)-selective ion channel located 
within the inner mitochondrial membrane Ca(2+) uniporter complex, and 
mutations disrupt mitochondrial Ca (2+) signaling.  
 
Mutations in ADCY5 are the most recently recognized significant cause of 
progressive chorea in children. Originally reported in patients presenting with 
familial dyskinesia with facial myokymia39. ADCY5-related disease comprise a 
wide clinical spectrum of disorders including those mimicking dyskinetic cerebral 
Movement Disorders in Childhood 
Kurian and Dale 2015 
 18 
palsy (CP) and conditions resembling TITF1-BHC40. A relapsing-remitting disease 
course is often evident, and severe sleep-disrupting movements are frequently 
reported. Unlike TITF1-BHC, motor symptoms are typically progressive. Eliciting 
a history of sleep disturbance and disease progression can thus aid clinical 
differentiation from BHC and CP. ADCY5 is a membrane-bound adenylyl cyclase 
that generates cyclic adenosine-3’,5’-monophosphate (cAMP) from an adenosine 
triphosphate (ATP). ADCY5 shows high expression in the brain striatum, and in 
the nucleus accumbens, where it is responsible for 80% of adenylate cyclase 
activation. β-adrenergic agonists stimulate ADCY5 through a G-protein-coupled 
receptor, which leads to a conformational change in the protein, facilitating 
formation of a catalytic pocket into which ATP binds. Pathogenic variants are 
predicted to lead to gain-of-function, increasing ADCY5 enzyme activity, either 
through β-adrenergic stimulation of the signal transduction pathway or by the 
interaction of the protein with other regulatory molecules. 
Insert Clinical Vignette Case 2 
 
(iii) Genetic Paroxysmal Movement Disorders  
A number of genetic movement disorders may present episodically (Table 3). 
Such paroxysmal dyskinesias typically present in childhood, often in children with 
normal neurodevelopment and behavior. Paroxysmal movements may be 
dystonic, choreiform, or ataxic and are often associated with specific triggers41. 
Detailed clinical history with direct questioning for precipitants of the movement 
disorder should be undertaken to aid diagnosis (Table 3). Many episodic 
movement disorders are caused by mutations in genes encoding channels, and 
therefore it is not surprising that such genes also account for other paroxysmal 
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disorders such as epilepsy and migraine (Table 3). Recognition of such 
syndromes is of significant clinical importance as many are amenable to treatment 
strategies (Table 3).  
 
(iv) Genetic Myoclonus 
Non-epileptic myoclonus is reported in a number of genetic conditions, often in 
association with other movement phenotypes. It is a prominent feature of 
myoclonus-dystonia syndrome [Section 4(i)] but also reported in a number of 
inherited inborn errors of metabolism [Section 4(vii)] 
 
(v) Genetic Ataxia 
A number of predominantly ataxic disorders of genetic origin are described in 
childhood (Table 4), and many are complex progressive neurological disorders. 
Friedreich’s ataxia (FA) is the most commonly reported, with clinical features of a 
progressive, mainly sensory cerebellar ataxia, with speech difficulties, absent 
reflexes, pyramidal tract signs with weakness, hypertrophic cardiomyopathy, 
diabetes and sensorineuroal deafness42. Expanded GAA repeats within intron 1 of 
frataxin (FRDA) are thought to impair exon splicing with reduced protein 
expression. Frataxin is postulated to have a role in mitochondrial iron metabolism 
and dyshomeostasis is thought to lead to increased free radical damage and 
oxidative stress. Ataxia with Vitamin E deficiency can mimic many of the features 
seen in FA, and is characterized by a progressive ataxia, with other cerebellar 
features of tremor, head titubation and nystagmus, as well as myoclonus, dystonia, 
hyporeflexia, and retinitis pigmentosa43 Disease is caused by mutations in the 
alpha-tocopherol transfer protein, with impaired incorporation of Vitamin E into 
Movement Disorders in Childhood 
Kurian and Dale 2015 
 20 
very low density lipoproteins, and subsequent excess loss of Vitamin E. Low 
Vitamin E levels are detectable on blood testing.  
 
Ataxia telangiectasia presents with gait disturbance and truncal instability in early 
childhood but choreiform movements and dystonia are also described44. Often 
subtle abnormalities in ambulation can precede the onset of ocular and cutaneous 
telangiectasia. Patients are at risk of immunodeficiency (secondary to low 
immunoglobulins) and lymphoreticular neoplasia. A raised alpha-fetoprotein can 
be a useful disease marker. Disease is due to mutations in ATM, encoding a DNA 
repair protein. Clinically similar to AT are two forms of autosomal recessive ataxia 
with oculomotor apraxia (AOA) due to mutations in ÂPTX (AOA1) and SCAR1 
(AOA2)45,46. Both types present with a distinctive eye movement disorder in 
context of ataxia, chorea, distal sensory axonal neuropathy and progressive 
cerebellar atrophy on MR brain imaging.  
 
Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) is a recently 
described condition originally in individuals originating from Quebec, Canada. 
ARSACS is caused by mutations in SACS, with over 100 reported mutations to date 
in patients if different ethnicities47. Ataxia, dysarthria, spasticity, weakness, distal 
sensorimotor neuropathy and nystagmus are commonly reported clinical 
symptoms. Distinctive neuroradiological features include atrophy of the superior 
vermis and cerebellum, with pontine linear hypointensities.  
 
A number of both dominant and recessive spinocerebellar ataxia disorders may 
also present in childhood with prominent ataxia and gait instability, as well as 
other movement phenotypes (dystonia, chorea), speech disturbance and 
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progressive motor dysfunction (Table 4). The increasing availability of targeted 
multiple gene panel testing for the ever-expanding list of SCA and other ataxia 
genes has improved the overall diagnostic rate for these childhood-onset 
ataxias,48 though detection of certain mutations (trinucelotide repeats, intronic 
variants) can still be challenging. 
 
 (vi) Genetic Parkinsonism 
Rarely, genetic disorders presenting predominantly with infantile or juvenile 
parkinsonism are reported2. Typically symptoms resemble those seen in 
idiopathic Parkinson’s disease, with bradykinesia, resting tremor, rigidity and 
hypomimia. Pure parkinsonism is rarely reported, with most patients manifesting 
other movement disorders, most commonly dystonia (parkinsonism-dystonia) 
but also chorea and myoclonus. Cognitive impairment may also be a co-morbid 
feature. A number of aetiologies are reported, including disorders of monoamine 
synthesis, metabolism and transport, as well as other inborn errors of metabolism 
(including mitochondrial disorders), disorders of brain metal ion accumulation 
and juvenile onset genetic parkinsonism due to mutations in the PARK genes 
(Table 3). Recognition of clinical features can be key to diagnosis, but adjunct 
tests, such as CSF neurotransmitter analysis, CSF and blood lactate, muscle biopsy, 
DaTSCAN nuclear imaging and molecular genetic studies will often be needed to 
confirm the diagnosis.  
 
(vii) Complex Inherited Neurometabolic Syndromes 
Movement disorders are often a prominent clinical feature in a number of inborn 
errors of metabolism that present in childhood. Many of these conditions are 
complex, and patients often manifest a number of different movement 
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phenotypes. Frequently there is multisystem disease involvement, with cognitive 
and motor delay.  
 
Dystonia, chorea, athetosis, ballismus, tremor, myoclonus and parkinsonism are 
all described in disorders of monoamine synthesis and transport27 (Table 5). The 
presence of eye movement disorders (oculogyric crises, ocular flutter, saccade 
initiation failure) as well as autonomic features (sweating, nasal congestion, 
temperature instability, ptosis) can be additional clinical features that raise 
clinical suspicion for these diseases, which can usually be diagnosed on CSF 
neurotransmitter analysis and confirmatory genetic studies. Patients with 
cerebral folate deficiency, for example, secondary to recessive mutations in the 
gene encoding the folate transporter FOLR1, can present with a number of non-
specific features including gait instability, hypotonia, seizures and acquired 
microcephaly49. Ataxia, chorea and ballsimus are also reported in a proportion of 
these patients.  
 
Inherited mineral deposition disorders, including Wilson’s disease, 
Neurodegeneration with Brain Iron Accumulation (NBIA) and SLC30A10 
Deficiency can all present with progressive neurological phenotypes50-52 and 
prominent extrapyramidal features including dystonia, chorea, tremor, 
parkinsonism and spasticity. Characteristic MR brain findings and molecular 
genetic testing can aid diagnosis of these disorders of metal ion accumulation 
(Table 5).  
 
A number of inborn errors of metabolism can present with movement disorders, 
including lysosomal disorders, mitochondrial diseases, amino acidopathies, 
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organic acidurias, disorders of purine and creatine metabolism and glucose 
transporter deficiency. Detailed metabolic screening is therefore often warranted 
in patients with complex progressive neurological syndromes associated with 
motor phenotypes (Table 5).  
 
More recently, a number of genes have been reported in infantile and childhood-
onset bilateral striatal necrosis (BSN) (Table 5). Mitochondriocytopathies are 
frequently associated with BSN. ADAR1 has emerged as an important cause, 
accounting for a significant proportion of patients with BSN presenting with 
severe, progressive, medically intractable generalized dystonia53. An interferon 
signature, measuring upregulation of interferon-stimulated genes can aid 
diagnosis of this BSN subtype. The finding of BSN should prompt a clinician to look 
for treatable causes including thiamine transporter deficiency due to mutations in 
SLC19A3, where instigation of biotin and thiamine supplementation can lead to 
marked improvement or even reversal of clinical symptoms in tandem with 
radiological improvement of the striatal features54.  
 
Structural abnormalities of the basal ganglia may also be seen in some genetic 
hypomyelinating disorders. In 2013, TUBB4A was identified as the genetic cause 
of hypomyelination with atrophy of the basal ganglia and cerebellum (H-ABC)55. 
Mutations are postulated to disrupt tubulin dimerization, microtubule 
polymerization, or microtubule stability. Extra-pyramidal features, namely 
dystonia, rigidity and rarely choreoathetosis are reported in affected patients. A 
number of patients also manifest ataxia and gait instability. TUBB4A-related 
diseases encompass a broad spectrum from H-ABC, to other hypomyelinating 
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disorders and also whispering dysphonia (Table 5). The reasons for this 
phenotypic pleiotropy remain to be fully elucidated56. 
 
(viii) Treatment Strategies for Genetic Childhood Movement Disorders 
Treatment strategies for children with genetic movement disorders are usually 
dictated by disease aetiology and movement disorder semiology. Children with 
dystonia of undetermined cause will often have an early trial of L-dopa to rule out 
a treatable dopa responsive dystonia27. Symptomatic treatment of dystonia is 
managed with a number of different agents including baclofen, trihexyphenidyl, 
the benzodiazepines57 and more recently clonidine and gabapentin. More invasive 
therapies such as intrathecal baclofen and deep brain stimulation (DBS) are also 
used. DBS is particularly effective for children with primary dystonia due to 
DYT158, but has also been used as palliation in a number of other genetic disorders 
such as pantothenate kinase associated neurodegeneration (PKAN). Chorea can 
often be difficult to manage from a therapeutic perspective but tetrabenazine, 
benzodiazepines and anti-epileptic drugs (levetiracetam, sodium valproate, 
carbamazepine) can be used59. The paroxysmal disorders have specific 
treatments, which can often be very effective (Table 4). Genetic parkinsonian 
disorders are treated with either L-dopa therapy or dopaminergic drugs such as 
pramipexole, ropinirole and rotigotine. Neurotransmitter disorders and other 
complex neurometabolic syndromes will require specific disease-targeted 
treatments, often necessitating consultation with a specialist in the field. All 
children with complex genetic syndromes should be under the care of a 
multidisciplinary team including a neurologist with expertise in movement 
disorders with close links to physiotherapy, occupational therapy and speech and 
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language therapists. Regular input from a general paediatrician to monitor general 
health issues, vision and hearing, and surveillance for orthopaedic and secondary 
gastrointestinal complications is also an integral part of routine care. Genetic 
counseling to discuss risk for future pregnancies should also be offered to affected 
families.  
 
Key Point 4:  
Genetic movement disorders are increasingly recognized and diagnosed in 
children. Often chromosomal microarray is an early investigation in such 
children, looking to identify copy number variants accounting for disease 
phenotypes. Further genetic testing is guided by clinical history, features on 
examination and radiological or metabolic biomarkers. The evolution of 
multiple gene panels and whole exome sequencing technologies has further 
improved diagnostic approaches for this group of patients. 
Insert Clinical Vignette Case 3 
(5) Psychogenic Movement Disorders in Children  
Psychogenic presentations represent a significant proportion of acute 
presentations to neurology services, and are important as they often represent a 
significant and complex issue for the child. Early recognition and treatment is 
considered important to provide the best chance of a good outcome. The issue of 
whether these problems should be termed ‘psychogenic’ or ‘functional’ is under 
debate but not discussed here, and there is little doubt that our understanding of 
these disorders is changing. Careful clinical history and observation is essential- 
sometimes the diagnosis is straightforward, however sometimes prolonged 
observation in difficult cases can be informative diagnostically. Psychogenic 
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movement disorders (PMD) occur more commonly in adolescents, and in females, 
and a diagnosis in a young child under 10 should be made with caution (although 
they do occur). The hallmarks of PMD are an acute often ‘explosive’ onset with a 
short time to maximum severity (often hours or day), incongruous characteristic 
(atypical or ‘odd’), inconsistent findings, inconsistent performance relative to the 
severity of movements (able to use mobile phone despite violent movements). 
‘Pseudo-myoclonus’ or ‘pseudo-tremor’ are the most common PMD movements, 
and pseudo-‘dystonia’, akinesia and chorea are uncommon although occasionally 
observed23. The classic patient may have a history of high performance in 
academic or sporting activity, a predisposition to anxiety, some preceding 
psychosocial stressors, and sometimes an acute, often minor, stress such as a 
dental procedure or infection.  
 
It is essential to approach the problem with care, empathy and perform necessary 
investigations to reassure the patient and family that there is no serious brain 
pathology such as a tumour. Neuroimaging is almost always necessary to 
progress. Explanation of the problem is important to the child and family, and this 
may require repeated consultations and discussions before the clinician and 
family accept the likely explanation. Arguably the most useful test can be a second 
opinion from an experienced colleague, although polymyography can be useful60. 
 
Key point 5:  
Early recognition and intervention of PMD, and involving a multi-
disciplinary team to rehabilitate the patient physically and psychologically 
is essential. Treating PMD can be rewarding to child, family and health 
practitioners.  
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[AU: Please provide a brief conclusion for your article that summarizes the 
points made in your article.] 
Insert Clinical Vignette Case 4 
(6) Clinical Vignettes 
Case 1:  
Clinical case: A previously well 7 year old Australian girl of Chinese descent 
presented with change in behaviour and restlessness. Over the following week, 
the illness progressed with increasing agitation, apparent delusional thoughts 
with repeated statements of ‘I’m going to die’. Examination revealed a generalized 
movement disorder with repetitive restless movements, scratching her face and 
cycling movements of her legs. In the second week she had 3 focal seizures and 
she became mute. MRI brain was normal, CSF showed 20 monocytes/mm3, and 
EEG showed non-specific slowing.  A clinical diagnosis of anti-NMDAR encephalitis 
was made and intravenous methylprednisolone was started for 5 days in addition 
to intravenous immunoglobulin. Ten days later there was no apparent 
improvement, she remained mute, unresponsive to her parents and environment 
despite being apparently awake, she only slept for 2 hours a night, and had 
ongoing purposeless, stereotypical repetitive movements of her limbs and face. 14 
days after commencing immune therapy, the CSF NMDAR antibodies returned 
positive, and given the lack of improvements, rituximab was started 375mg/m2 
weekly for 4 weeks. 10 days after starting rituximab she started to make 
improvements, her movement disorder evolved to dystonic posturing, but she 
became more interactive and less agitated. After a 2-month admission, she was 
discharged on a 6 month total oral prednisolone taper. She remained B cell 
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depleted for 6 months, and continued to improve. At 12 months all of her 
symptoms had resolved, although her school performance was slightly behind.  
Comment: The case exemplifies the movement phenomenology in anti-NMDAR 
encephalitis with restless stereotypical movements, later followed by dystonia. The 
case also exemplifies the fact that the movement disorder rarely occurs in isolation, 
and is almost always accompanied by other changes in neurological function- in this 
case cognitive changes, loss of speech, seizures and agitated psychosis. The case also 
demonstrates it is possible to make a clinical diagnosis and start treatment before 
getting confirmatory diagnostic results. A positive antibody result empowers the 
clinician to use rituximab or other immune suppression if the patient does not 
adequately respond to first line therapy.  
Case 2:  
Clinical case: A male infant was born to fit and healthy parents, with no significant 
family history of note. Following an unremarkable pregnancy, he was delivered by 
emergency Caesarian section for fetal bradycardia/decelerations. He was born in 
good condition, with excellent APGAR scores (91, 105) and had an uneventful early 
neonatal course, not requiring admission to the Special Care Baby Unit. Abnormal 
involuntary movements were noted from mid-infancy, which were initially 
paroxysmal in nature, occurring in clusters often several times a day, with periods 
of relapse and remission. Choreiform limb movements were reported, with 
orolingual dyskinesia and mild truncal athetosis. Over time through early 
childhood, the movement disorder progressed, eventually becoming 
nonparoxysmal and continuous in nature. Furthermore, involuntary movements 
began to disrupt his sleeping pattern. He did not show clinical response to a 
number medications, including carbamazepine, levetiracetam and tetrabenazine. 
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Detailed neurological investigation revealed normal MR brain and spinal imaging, 
as well as normal blood, urine and CSF screening for metabolic disorders. Routine 
diagnostic testing for NKX.2.1, SLC2A1 and SGCE were negative. Whole exome 
sequencing undertaken on a research basis identified a previously reported 
mutation in ADCY5, which was confirmed to be de novo. 
Comment: This clinical case clearly exemplifies the typical disease pattern of 
ADCY5-related disease. Although dyskinetic cerebral palsy may be one of the 
differential diagnosis here, a number of features in his history should prompt 
investigation of an alternative cause, including (i) the relatively uneventful 
antenatal/ postnatal course (ii) evidence of normal neuroimaging (iii) clear disease 
progression with worsening of symptoms. Testing for BHC is reasonable, but 
negative sequencing for NKX2.1 should alert the clinician to look for other causes of 
BHC mimics, and instigate ADCY5 testing. Further clinical clues towards this 
diagnosis include the disruption of sleep and progressive nature of disease. 
Case 3:  
Clinical Case: A female infant was born to fit and healthy consanguineous parents. 
She was born in good condition and did not require any resuscitation, nor was she 
admitted to the Neonatal Intensive Care Unit. She was discharged on Day 2 of life. 
From the early neonatal period, she was irritable, with difficulty in feeding and a 
disrupted sleep pattern. The parents described that often she would look as if she 
was “half asleep”, with her eyes half-closed. She was profoundly hypotonic and 
had delay in her motor milestones. By 2-3 months of age, abnormal eye 
movements were noted, and the family described periods lasting from seconds to 
several hours, when her eyes would deviate to the right and fixate in upward gaze. 
Often during these periods her body would be arched and hands fisted.  The 
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parents also noted that she always seems to have a cold, with nasal congestion and 
even during the winter, her hands and the back of her head were sweaty. During 
infancy she developed a complex movement disorder, with dystonic posturing of 
her limbs, truncal athetosis, tremulous hand movements and occasional 
myoclonic jerks. A diagnostic lumber puncture was undertaken and CSF 
neurotransmitter analysis revealed a low homovanillic, low 5-
hydroxyindoleacetic acid and normal pterin profile. CSF 3-O-methyl dopa and 5-
hydroxytryptophan were markedly elevated. Further testing revealed low AADC 
plasma enzyme activity. Molecular testing revealed that she was a compound 
heterozygote for two mutations in the DDC gene, one reported in association with 
AADC deficiency and the other a novel 2 base pair deletion. 
Comment: This case illustrates a child with a very early-onset neurological disorder, 
characterized by severe motor delay, hypotonia and mixed movement semiology. 
The ptosis and severe hypotonia could indeed be presenting features of 
neuromuscular disease, though the complex movement disorder and presence of 
autonomic features (sweating, nasal congestion, ptosis) should prompt CSF 
neurotransmitter analysis to look for disorders of monoamine metabolism. CSF 
findings are indeed classical for AADC deficiency, later confirmed by enzyme assay 
and molecular genetic testing. The first mutation is already reported in the literature 
associated with AADC deficienct. The second mutation, though novel, as a 2 base pair 
deletion, will lead to a frameshift with significant alteration to the protein and likely 
premature stop.  
Case 4:  
A 12 year old girl with no significant medical problems presented with shaking 
movements of the arms. She had attended school normally the day before, but had 
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onset of shaking movements the preceding evening, which had deteriorated 
dramatically over the course of the next day. There was no other change in 
function. Examination revealed dramatic coarse shaking of the upper limbs but no 
abnormal movements of the legs, head or trunk. Her walking revealed 
unsteadiness with significant wobbling during walking but without falls. During 
observation on the ward, it was noted that her symptoms fluctuated significantly, 
and she was observed to use her mobile phone normally without shaking, and her 
shake varied according to the people around her. Her behaviour, thinking and 
memory was normal, and formal neurological examination was also normal. On 
subsequent history, it became apparent that she had been the victim of significant 
bullying at school. The school described her as a kind diligent and sensitive girl 
who was training 5 nights at week at state-level netball. MRI brain and EEG were 
normal.  
Comment: The incongruous and inconsistent nature of the movement disorder lead 
to a diagnosis of psychogenic movement disorder, presumably secondary to the 
significant stressors. Psychological input uncovered some baseline anxiety and fears 
of failure with perfectionism and some obsessive-compulsive behaviour. A confident 
diagnosis, acceptance of the diagnosis by the family followed by a multi-disciplinary 
rehabilitation with physiotherapy and psychological inputs resulted in a rapid 
improvement and return to normal function.  
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Table 1: Benign Movement Disorders of Childhood  
Condition Symptom 
onset 
Average Age at 
Symptom Resolution 
Clinical Features Associated Aetiology 
Jitteriness Neonatal 
period 
Mid-infancy Generalised rhythmic oscillation  Hypoxic ischaemic encephalopathy 
 Hypoglycaemia 
 Hypocalcaemia 
 Drug withdrawal 
Benign Neonatal Sleep 
Myoclonus 
Neonatal 
period 
Mid-infancy Repeated myoclonic jerks in sleep  
Benign Myoclonus of 
Early Infancy 
Infancy Usually by 2 years Myoclonic spasms neck, trunk and limbs, like 
infantile spasms 
 
Spasmus Nutans Infancy Within few months, 
nystagmus can persist 
Horizontal/ vertical head tremor with 
pendular nystagmus 
 Rarely cerebellar abnormalities on 
neuroimaging 
Infantile Masturbation Infancy  Limb posturing, rocking, thigh adduction with 
genital manipulation/pressure over pubic 
area 
 
Shuddering Infancy – end of 
the first decade 
Usually get better with 
age 
Shivering movements of head, shoulders and 
upper limbs often with facial grimace 
 
Benign Idiopathic 
Dystonia of Infancy 
 
Infancy Usually by 1 year Segmental dystonia, usually upper limb  
Benign Paroxysmal 
Torticollis of Infancy 
Infancy Mid-childhood Paroxysmal head tilt, often with vomiting 
irritability, pallor, s 
 Mutations in CACNA1A 
 Mutation in PRRT2 
Paroxysmal Tonic 
Upgaze of Infancy 
Infancy Mid-childhood Paroxysmal deviation of eyes 
upward/downward 
 Mutations in CACNA1A 
 Hypomyelination 
 Periventricular leukomalacia 
 Vein of Galen malformation 
 Pinealoma 
Head nodding Usually by 
early childhood 
Normally resolve in a 
few months, but may 
last through childhood 
Horizontal, vertical and oblique head 
movements 
 Onchocerca volvulus infection (sub 
Saharan Africa) 
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Table 2: DYT classification of primary genetic dystonia in childhood   
DYT 
Number 
Clinical presentation  Pattern of Inheritance Causative Gene 
DYT1 Early onset primary generalized 
idiopathic torsion dystonia 
Autosomal dominant TOR1A 
DYT5a 
 
Dopa responsive dystonia Autosomal dominant GCH1 
DYT5b 
 
Tyrosine hydroxylase deficiency Autosomal recessive TH 
DYT8 
 
Paroxysmal non-kinesogenic dyskinesia Autosomal dominant  MR-1 
DYT10 
 
Paroxysmal kinesogenic dyskinesia Autosomal dominant PRRT2 
DYT11 
 
Myoclonus-dystonia  Autosomal dominant SGCE 
DYT12 Rapid onset childhood dystonia-
parkinsonism 
Autosomal dominant ATP1A3 
DYT18 
 
Paroxysmal exercise induced dyskinesia Autosomal dominant SLC2A1 
DYT23 
 
Myoclonus dystonia Autosomal dominant CACNA1B 
DYT26 
 
Myoclonus dystonia Autosomal dominant KCTD17 
 
Non-paroxysmal dystonias that may present in childhood are highlighted in red 
Paroxysmal Disorders that may present in childhood are highlighted in blue
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Table 3: Clinical Features of Commoner Genetic Paroxysmal Disorders 
 
Disorder Age of onset Reported 
triggers 
Duration 
of episode  
Medication Causative 
Gene 
Allelic disorders 
Paroxysmal 
kinesogenic dyskinesia 
Infancy – 4th 
decade 
Sudden movement Short – 
seconds to 
minutes 
Carbamazepine 
Phenytoin 
PRRT2  ICCA infantile convulsions, choreoathetosis 
 Benign paroxysmal torticollis of infancy 
 Familial migraine 
Paroxysmal non-
kinesogenic dyskinesia 
Infancy – 4th 
decade 
Caffeine 
Alcohol 
Stress/anxiety 
Sleep deprivation 
Longer – 
minutes to 
hours 
Benzodiazepines MR-1  
Paroxysmal exercise 
induced dyskinesia 
Infancy – 
adulthood 
Exercise 
Stress 
Fasting 
Longer –
minutes to 
hours 
Ketogenic diet SLC2A1  Glucose transporter deficiency phenotypes: 
 Absence epilepsy 
 Myoclonic-atonic epilepsy 
 Generalised epilepsy 
 Early infantile epileptic encephalopathy 
Alternating Hemiplegia 
of Childhood 
Infancy – 
early 
childhood 
Unclear Minutes Flunarizine ATP1A3  Rapid onset dystonia parkinsonism 
 CAPOS 
Episodic Ataxia Type 1 Childhood Sudden movement 
Stress 
Exertion 
Fatigue 
Illness 
Short – 
seconds to 
minutes 
Acetazolamide 
Carbamazepine 
KCNA1  
Episodic Ataxia Type 2 Childhood – 
adolescence 
Sudden movement 
Stress 
Exertion,exercise 
Fatigue 
Caffeine 
Alcohol 
Cigarettes 
Very long – 
hours to 
days 
Flunarazine 
Acetazolamide 
 
 
CACNA1A  Spinocerebellar ataxia 6 
 Familial hemiplegic migrane 
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Table 4: Childhood Onset Genetic Disorders with Prominent Ataxia 
 
Condition Inheritance  Gene(s) Age of 
Presentation 
Movement semiology 
Friedreich’s Ataxia AR FRDA Childhood  
2-15years 
Ataxia 
Ataxia with Isolated 
Vitamin E deficiency 
AR Alpha tocopherol 
transfer protein 
Childhood Ataxia 
Other cerebellar features: tremor, nystagmus 
Ataxia Telangectasia AR  Early 
Childhood <5 
years 
Ataxia 
Chorea 
Athetosis 
Dystonia 
Eye movement abnormalities 
Ataxia Oculomotor 
Apraxia (AOA) 
AR ÂPTX (AOA1) 
SCAR1 (AOA2) 
Mid-, later 
Childhood 
Ataxia 
Oculomotor apraxia 
Chorea, athetosis 
Autosomal Recessive 
Spastic Ataxia of 
Charlevoix-Saguenay 
AR SACS Childhood – 
adulthood 
Ataxia 
Spinocerebellar Ataxia 
(SCA) 
AD and AR Many genes 
including 
SCA1 Ataxin  
SCA2 Ataxin  
SCA3 MJD1 
SCA7 
Childhood-
adulthood 
Ataxia 
Dystonia and chorea also sometimes present 
Parkinsonism 
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Table 5:  Pediatric Parkinsonism and Complex Neurometabolic Syndromes 
 
Group of 
Disorders 
Typical Age of Onset Syndrome/Condition Reported motor phenotypes  Useful diagnostic 
tests/disease biomarkers 
Causative 
Genes 
(molecular 
confirmation) 
Monogenic early 
onset 
parkinsonism 
(PARK loci) 
Childhood/ 
adolescence/early 
adulthood 
Juvenile parkinsonism Parkinsonism 
Dystonia 
 
DaTSCAN 
Prolactin 
PARK2 
DNAJC6 
PINK1 
DJ1 
SNCA  
LRRK2 
VPS35 
EIFG41 
SYNJ1 
PD8B 
Monoamine 
neurotransmitter 
disorders 
Infancy/ 
childhood/adulthood 
Autosomal dominant GTP 
cyclohydrolase deficiency  
Dystonia 
Parkinsonism  
Tremor 
CSF neurotransmitters 
Phenylalanine loading  
Trial of L-dopa 
GCH1 
 Infancy/ early 
childhood 
Autosomal recessive GTP 
cyclohydrolase deficiency 
Dystonia 
Hypotonia 
CSF Neurotransmitters 
 
GCH1 
 Infancy 6 Pyruvoyl-tetrahydropterin 
synthase (PTPS) deficiency 
Parkinsonism 
Dystonia 
Chorea 
Oculogyric crises 
CSF Neurotransmitters 
 
PTS 
 Infancy Sepiapterin reducase deficiency Dystonia 
Oculogyric crises 
Dyskinesia 
“CP mimic” 
CSF neurotransmitters 
Phenylalanine loading  
Serum Prolactin 
 
SPR 
 Infancy Dihydropteridine reductase 
(DHPR) deficiency 
Dyskinesia 
Choreoathetosis 
CSF neurotransmitters QDPR 
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Dystonia 
Tremor 
 Infancy  Aromatic L-amino acid 
decarboxylase (AADC) 
deficiency 
Hypotonia 
Dystonia 
Dyskinesia 
Hypokinesia 
Oculogyric crises 
CSF neurotransmitters 
AADC plasma activity 
Serum prolactin 
Urine organic acids 
 
DDC 
 Infancy  Dopamine Transporter 
Deficiency Syndrome 
Dystonia 
Chorea 
Orolingual dyskinesia 
Axial hypotonia 
Later parkinsonism 
Oculogyric crises and eye 
movement disorder 
“CP mimic” 
CSF Neurotransmitters 
DaTSCAN 
 
SLC6A3 
 Infancy Brain Dopamine Serotonin 
Transport Disease 
Dystonia 
Parkinsonism 
Axial hypotonia 
Dyskinesia 
Oculogyric crisis 
 VMAT2 
Other inborn 
errors of 
metabolism 
Infancy Lysosomal disorders 
GM1 Gangliosidosis 
GM2 Gangliosidosis 
Niemann Pick C (NPC) 
Gaucher Disease 
Neuronal Ceroid lipofucinosis 
 
Ataxia 
Dystonia 
Chorea 
Parkinsonism 
Supranuclear gaze palsy (NPC)  
Gaucher carrier –Parkinson 
disease risk 
 
Lysosomal enzyme assay 
 
GLB1 
GM2A 
NPC1, NPC2 
GBA1 
CLN1-11 
 Infancy Organic acidurias 
Glutaric Acidura Type 1 
 
 
Hyperkinesia 
Dystonia 
 
OA: glutaric acid, 3-
hydroxyglutaric acid 
 
GCDH 
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Methylmalonic aciduria 
 
 
 
 
Proprionic acidemia 
Choreoathetosis 
 
 
 
 
 
 
 
 
 
 
Dystonia, hypotonia 
 
 
 
 
Dystonia 
Choreoathetosis 
Spasticity 
Fibrobast assay: reduced 
glutaryl-CoA 
dehydrogenase activity 
Acylcarnitines: 
glutyrylcarnitine  
MRI scan – enlarged 
subdural spaces, 
frontotemporal atrophy, 
bat-winged dilatation of 
Sylvian fissures 
 
OA: elevated MMA 
Hyperammonaemia 
Hypoglycaemia 
Metabolic acidosis 
 
OA: elevated PA 
Metabolic acidosis 
Hyperammonaemia 
Hyperglycinaemia 
 
 
 
 
 
 
 
 
 
 
 
MUT 
 
 
 
 
PCCB, PCCA 
 Infancy Aminoacidopathies 
Homocystinuria 
 
 
 
Harntnup disease 
 
 
Dystonia 
 
 
 
Ataxia, spasticity, dystonia 
 
 
Abnormal plasma and urine 
homocysteine 
 
CBS, MTRR, 
MTRMMACHC, 
MTHFR etc 
 
SLC6A19 
 Infancy Disorders of purine 
metabolism 
Lesch-Nyhan disease 
 
 
Choreoathetosis, dystonia, 
hypotonia, spasticity 
 
 
Hyperuricaemia 
 
 
 
HPRT 
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 Infancy Disorders of creatine 
metabolism 
Guanidinoacetate 
methyltransferase (GAMT) 
deficiency 
 
 
Dystonia, choreoathetosis 
 
 
MRS: low creatine peak 
Urine: low creatine, high 
guanidinoacetate 
 
 
GAMT 
 Infancy/ childhood/ 
adulthood 
Glucose transporter 
deficiency 
 
Dystonia 
Choreoathetosis 
Ataxia 
Often paroxysmal symptoms 
Low CSF glucose 
Low CSF:plasma glucose 
ratio 
SLC2A1 
 Infancy Cerebral folate deficiency Ataxia 
Dystonia 
Chorea 
Low 5-
methyltetrahydrofolate on 
CSF analysis 
FOLR1 
DHFR 
MTHFR 
GJA12 
 Infancy/ childhood/ 
adulthood 
Mitochondrial   
Disorders  
Numerous, including 
Leigh syndrome 
POLG1-related disease 
Pyruvate carboxylase deficiency 
Lebers Hereditary Optic 
Neuropathy plus Dystonia 
 
 
Dystonia 
Myoclonus 
Choreoathetosis 
Parkinsonism 
Tremor 
Ataxia 
 
 
 
Lactate, organic acids 
Muscle biopsy respiratory 
chain enzyme analysis 
 
 
Numerous 
mitochondrial 
DNA point 
mutations and 
autosomal genes 
Striatal disorders Infancy Bilateral striatal necrosis Progressive dystonia 
 
 
 
 
MRI: bilateral striatal 
necrosis 
ADAR1: Interferon 
signature 
 
 
 
ADAR1  
ATP6,5 
ND1, ND6 
NDUFV1 
NUP62 
SLC19A3, 
SLC25A19 
ADAR1 
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Disorders of Metal 
Ion Accumulation 
     
Iron Childhood Pantothenate Kinase Associated 
Neurodegeneration (PKAN) 
Early gait disturbance 
Progressive dystonia 
Spasticity 
MRI:  
Eye-of –the –tiger in GP 
Blood film  -acanthocytes 
Retinal pigmentation 
 
PANK2 
 Infancy/ childhood/ 
adulthood 
Phospholipase A2-associated 
Neurodegeneration (PLAN) 
Infantile neuroaxonal 
dystrophy (INAD) – dystonia, 
spasticity 
Atypical neuroaxonal 
dystrophy (NAD) – dystonia, 
spasticity 
PLA2G6-related dystonia-
parkinsonism -subacute onset 
of dystonia-parkinsonism, 
spasticity 
MRI:  
Brain iron (NAD, INAD) in 
GP and SN 
Cerebellar atrophy/gliosis 
Optic atrophy 
 
EEG: (INAD) – fast rhythms 
EMG/NCS: distal sensory 
axonal neuropathy 
PLA2G6 
 Childhood Mitochondrial Membrane 
Protein Associated 
Neurodegeneration (MPAN) 
Dystonia 
Spasticity 
MRI: 
Brain iron in GP and SN 
Linear streaking of medial 
medullary lamina between 
globus pallidus externa and 
interna 
C19orf12 
 Infancy/ Childhood Beta propeller protein 
Associated Neurodegeneration 
(BPAN) 
Early delay, stereotypies 
Later development of 
dystonia-parkinsonism 
MRI 
Brain iron in SN and GP 
T1 “halo” in SN 
WDR45 
 Childhood Fatty acid hydroxylase-
associated Neurodegeneration 
(FAHN) 
Focal dystonia 
Spasticity with gait 
disturbance 
Later ataxia 
MRI: 
Brai iron in SN and GP 
Cerebellar and brainstem 
atrophy 
White matter changes 
FA2H 
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CSF: Cerebrospinal fluid 
MMA: Methylmalonic acid 
MRS: Magnetic resonance spectroscopy 
OA: Organic acids 
 
  COASY protein associated 
Neurodegeneration (CoPAN) 
Dystonia 
Spasticity 
Parkinsonism 
MRI: 
Brain iron in GP and SN 
 
COASY 
Manganese Childhood/ 
adulthood 
Manganese Transporter Defect Dystonia 
Parkinsonism 
 
MRI: 
T1-weighted 
hyperintensity of basal 
ganglia, midbrain and 
cerebellum 
 
Raised blood manganese 
levels 
SLC30A10 
Copper Childhood/ 
adulthood 
Wilson’s Disease Dystonia 
Parkinsonism 
Tremor 
Choreoathetosis 
Ataxia 
MRI: 
T2-weighted 
hyperintensity in putamen 
and thalami, midbrain face 
of the giant panda sign 
 
Kaiser Flesicher rings on 
slit lamp eye examination 
 
Copper, caeruloplasmin, 
urinary copper profile 
ATB7B 
Other Infancy/ childhood Hypomyelination with atrophy 
of the basal ganglia and 
cerebellum (H-ABC) 
Dystonia 
Choreoathetosis 
 
MRI: hypomyelination, 
basal ganglia and cerebellar 
atrophy 
TUBB4A 
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PA: Propionic acid 
 
